Xinteza API Ltd., a biosynthesis technology company, revealed the discovery of a new catalytic enzyme, capable of solving one of the major bottlenecks that has so far limited the design of sustainable and cost-efficient cannabinoid biosynthesis production systems, in research led by professor Asaph Aharoni at the Weizmann Institute of Science.

Xinteza has recently unveiled discoveries for a patent-pending whole new non-cannabis source of cannabinoid biosynthesis related genes and enzymes. This newly discovered gene pool includes a novel prenyl-transferase enzyme.

The prenylation stage in cannabinoid biosynthesis is the last and major step in the formation …

Full story available on Benzinga.com